Pramodini Medicare Ltd H1 FY27 Profit Falls 9.8% to ₹8.3 Crore

Pramodini Medicare Ltd reported net profit of ₹8.3 crore for H1 FY27, down 9.8% year on year, despite revenue from operations rising 33.9% to ₹37.1 crore for the half year ended September 30, 2026. The results point to lower profitability alongside stronger revenue growth.

What did Pramodini Medicare report for H1 FY27?

Pramodini Medicare Ltd reported total income of ₹37.6 crore in H1 FY27, compared with ₹28.3 crore in H1 FY26. Revenue from operations rose to ₹37.1 crore from ₹27.7 crore, while other income was unchanged at ₹0.5 crore.

Net profit declined to ₹8.3 crore from ₹9.2 crore in the corresponding half of the previous financial year. Profit before exceptional items and tax, which was also the reported profit before tax, stood at ₹10.7 crore, compared with ₹12.3 crore a year earlier.

The filing showed that operating profit declined 13.6% year on year even as operating revenue expanded. Operating margin declined to 28.5% from 43.5%, indicating that the increase in revenue did not translate into a similar increase in operating profitability during the period.

When did Pramodini Medicare file the H1 FY27 results?

Pramodini Medicare filed its April-September 2026 financial results with the National Stock Exchange of India on November 13, 2026, at 19:09 IST. The filing was made 44 days after the end of the half year on September 30, 2026.

The company's board met on November 13 to consider the Q2 FY27 results, covering July-September 2026. The reported H1 numbers cover both the first and second quarters of FY27 rather than only the September quarter.

The results information identifies the figures as consolidated results. Separate disclosures also said the board approved unaudited standalone and consolidated financial results for the half year ended September 30, 2026. The available summary does not provide a separate set of quarterly financial figures in the reported data.

Why did revenue growth not lift Pramodini Medicare's profit?

Pramodini Medicare's reported financial data shows that profitability fell despite higher revenue, as operating profit decreased 13.6% year on year and operating margin contracted by 15 percentage points. The filing summary does not state a specific reason for the margin decline.

The movement in profit before tax is consistent with the lower net profit. Profit before tax fell by ₹1.6 crore to ₹10.7 crore, while total income rose by ₹9.3 crore. Investors therefore have a clear divergence to assess between top-line growth and profit conversion.

Other income remained at ₹0.5 crore in both comparable periods. This means the reported improvement in total income was primarily driven by revenue from operations, while the lower profit figures and operating margin reflected changes in the underlying cost and operating profile that are not detailed in the available results summary.

How are IPO proceeds being used by Pramodini Medicare?

Pramodini Medicare disclosed total IPO proceeds of ₹69.04 crore and said ₹36.03 crore remained unutilised as of September 30, 2026. It also reported IPO net proceeds of ₹56.03 crore, of which ₹20 crore had been utilised by that date.

The disclosed uses include capital expenditure on medical equipment and general corporate purposes. The company said there were no deviations in the utilisation of IPO proceeds as of September 30, based on the information included with the results-related disclosure.

The board also approved the constitution of an ESOP Committee with four members, including Managing Director Kuldeep Kumar Chalasani. In another corporate announcement, Pramodini Medicare appointed Purva Sharegistry India Pvt Ltd as its Registrar and Share Transfer Agent in compliance with Securities and Exchange Board of India regulations.

What does the H1 result mean for investors and operations?

Pramodini Medicare's H1 FY27 report presents stronger revenue growth but weaker earnings and margins. For investors, the key reported measures are the 33.9% increase in revenue from operations, the 9.8% decline in net profit, and the reduction in operating margin to 28.5%.

The half-year result follows a period of revenue expansion in the company's annual financial history. The latest full-year information available for FY26 showed total revenue of ₹62.288 crore, net income of ₹17.377 crore and operating income of ₹23.513 crore. The annual income-statement trend also listed sales of ₹62 crore for FY26, compared with ₹38 crore for FY25.

Pramodini Medicare operates in technology-enabled diagnostic services across radiology and clinical laboratory services, according to the provided company description. The stated use of IPO funds for medical equipment makes capital deployment relevant to its operating capacity, but the company has not provided an outcome or financial contribution from that spending in the disclosed material.

Conclusion

Pramodini Medicare reported a mixed H1 FY27 financial performance: revenue from operations increased to ₹37.1 crore, but net profit fell to ₹8.3 crore and operating margin reduced to 28.5%. The reported figures place the focus on profitability and operating costs rather than revenue growth alone.

The next disclosures to watch are the company's subsequent financial results and updates on the ₹36.03 crore of IPO proceeds that remained unutilised as of September 30, 2026. Investors can also monitor whether future filings provide more detail on the factors behind the margin and operating-profit movement.